Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivipansel OLE in Sickle Cell Disease VOC
NCT02433158Phase 3Terminated
- Sponsor
- GlycoMimetics
- Start
- Dec 2015
- Primary completion
- Nov 2019
- Modality
- Bivalent/Multivalent Binders, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of rivipansel in sickle cell disease (SCD), sponsored by GlycoMimetics. Started Dec 2015; status: terminated.
02
Drugs
rivipansel
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02433158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02433158.